Kneat.com, Inc. (KSIOF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kneat.com, Inc. (KSIOF) trades at $4.60 with AI Score 63/100 (Grade B+). Kneat. com, Inc. Market cap: $442M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for KSIOF: KSIOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KSIOF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
KSIOF: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Kneat.com, Inc. (KSIOF) Healthcare & Pipeline Overview
Kneat.com, Inc. delivers the Kneat Gx platform, a configurable commercial off-the-shelf software designed for comprehensive validation lifecycle management in biotechnology, pharmaceutical, and medical device manufacturing. Operating globally from Limerick, Ireland, the company addresses critical data and document management needs within highly regulated industries, supported by a full suite of implementation and consulting services.
What Is the Investment Thesis for KSIOF?
Kneat.com, Inc. presents an investment thesis centered on the increasing demand for digital transformation and automation within highly regulated life sciences sectors. The company's flagship Kneat Gx platform, a specialized COTS solution for validation lifecycle management, addresses a critical and complex need for pharmaceutical, biotechnology, and medical device manufacturers. With a strong gross margin of 76.6%, the company demonstrates efficient cost management relative to its revenue. Key growth catalysts include the ongoing industry shift towards digitized compliance workflows, potential expansion into new geographic markets, and continuous platform enhancements to meet evolving regulatory requirements. However, the company currently operates with a negative profit margin of -12.7% and a negative ROE of -13.0%, indicating it is not yet profitable. Additionally, its OTC Other tier listing suggests higher risk and lower liquidity compared to major exchanges, which investors must consider. The ability to scale operations efficiently and convert its strong gross margin into sustained profitability will be crucial value drivers.
Based on FMP financials and quantitative analysis
KSIOF Key Highlights
- Market capitalization stands at $0.44 billion, reflecting its current valuation in the specialized software market.
- Achieved a robust gross margin of 76.6%, indicating strong cost control over its core software and service offerings.
- Currently reports a profit margin of -12.7%, highlighting ongoing investments or operational costs exceeding revenue.
- Return on Equity (ROE) is -13.0%, consistent with its current unprofitability.
- Maintains a Debt-to-Equity (D/E) ratio of 42.42, indicating a moderate reliance on debt financing.
- Employs 297 individuals, supporting its global operations and software development.
Who Are KSIOF's Competitors?
KSIOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NRC National Research Corporation | $20.83 | -3.52% | $469M | 70 |
| SOPH SOPHiA GENETICS SA | $6.05 | -5.47% | $416M | 58 |
| SLGCW SomaLogic, Inc. | $0.09 | -28.33% | $396M | 55 |
| SLGC SomaLogic, Inc. | $2.10 | -4.55% | $396M | 55 |
| TBRG TruBridge, Inc. | $26.24 | +0.00% | $394M | 70 |
| SLP Simulations Plus, Inc. | $18.33 | +0.44% | $371M | 81 |
| ACCD Accolade, Inc. | $7.02 | +0.00% | $576M | 55 |
| PHR Phreesia, Inc. | $9.80 | -2.10% | $606M | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KSIOF's Key Strengths?
- Specialized Kneat Gx platform addresses a critical niche in highly regulated industries.
- Strong gross margin of 76.6% indicates efficient core operations.
- Comprehensive suite of professional services enhances customer value and retention.
- Global operational presence across key markets (US, Ireland, Canada).
What Are KSIOF's Weaknesses?
- Currently unprofitable with a profit margin of -12.7% and ROE of -13.0%.
- OTC Other tier listing implies higher risk and lower liquidity for investors.
- Reliance on the highly regulated life sciences sector, which can be subject to unpredictable changes.
- Potential for high customer acquisition costs in a specialized enterprise software market.
What Could Drive KSIOF Stock Higher?
- Increased enterprise client adoption of the Kneat Gx platform, driving revenue growth.
- Continued digital transformation initiatives within the biotechnology and pharmaceutical industries, expanding the addressable market.
- Introduction of new features or modules for the Kneat Gx platform, enhancing its value proposition and market appeal.
- Strategic partnerships or geographic expansion into new regulated markets, broadening the company's reach.
What Are the Key Risks for KSIOF?
- Negative return on equity (-12.9%) — the business is not currently generating profit on shareholder capital.
- Sustained negative profit margin and Return on Equity (ROE) indicate a lack of profitability.
- Intense competition in the specialized regulatory software market from both niche players and larger enterprise solution providers.
- Adverse changes in regulatory requirements within the life sciences sector, which could impact demand for or necessitate costly modifications to the Kneat Gx platform.
- Risks associated with trading on the OTC Other tier, including lower liquidity and potentially limited public disclosure.
- Economic downturns or reduced R&D spending in the biotechnology and pharmaceutical industries, affecting client budgets for new software.
What Are the Growth Opportunities for KSIOF?
- Expanding Adoption within Existing Regulated Sectors: Kneat.com, Inc. has a significant opportunity to deepen its penetration within the biotechnology, pharmaceutical, and medical device manufacturing industries. As these sectors continue their digital transformation journeys, the demand for specialized, compliant software like Kneat Gx is expected to grow. The market for life sciences R&D software, which includes validation management, is projected to expand, driven by increasing drug development and stringent regulatory oversight. By demonstrating clear ROI through reduced validation times and improved compliance, Kneat.com can secure more enterprise clients and expand its footprint within existing customer organizations, potentially through additional modules or broader deployment across client sites.
- Geographic Market Expansion: While Kneat.com, Inc. currently operates in the United States, Ireland, and Canada, there is substantial potential for expansion into other highly regulated markets globally. Regions with robust pharmaceutical and biotechnology industries, such as Western Europe (beyond Ireland), parts of Asia, and Latin America, represent untapped markets where similar regulatory pressures and needs for digital validation exist. Strategic partnerships or direct market entry into these regions, supported by localized compliance expertise, could unlock new revenue streams and significantly broaden the company's addressable market over the next 3-5 years.
- Enhancement and Diversification of the Kneat Gx Platform: Continuous innovation and the introduction of new features or modules within the Kneat Gx platform represent a key growth driver. As regulatory landscapes evolve and technological capabilities advance, Kneat.com can expand the platform's functionality to cover additional compliance areas, integrate with other enterprise systems (e.g., LIMS, ERP), or leverage emerging technologies like AI for predictive analytics in validation. These enhancements can increase the platform's value proposition, attract new customers, and provide opportunities for upselling to existing clients, ensuring long-term relevance and competitive advantage in the dynamic software market.
- Increased Demand for COTS Validation Solutions: The trend towards commercial off-the-shelf (COTS) software solutions for critical business processes, including validation, is accelerating. Companies in regulated industries are increasingly recognizing the benefits of COTS platforms over custom-built or paper-based systems, including faster deployment, lower maintenance costs, and inherent compliance features. Kneat.com, with its purpose-built Kneat Gx platform, is well-positioned to capitalize on this shift. The market for COTS solutions in life sciences is expected to grow as organizations seek to standardize and streamline operations, presenting a multi-year growth opportunity for Kneat.com by offering a proven, scalable, and compliant solution.
- Expansion of Professional Services Offerings: Beyond software licensing, Kneat.com's comprehensive suite of services—including implementation, training, consulting, and maintenance—represents a significant growth opportunity. As the client base expands and the complexity of deployments increases, the demand for these high-margin professional services will also grow. The company can further develop specialized consulting services, such as regulatory advisory or process optimization, to become a more integral partner to its clients. This not only generates additional revenue but also strengthens customer relationships and ensures successful long-term adoption of the Kneat Gx platform, contributing to recurring revenue streams over time.
What Opportunities Does KSIOF Have?
- Increasing demand for digital transformation and automation in regulated industries.
- Expansion into new geographic markets beyond current operations.
- Further development and enhancement of the Kneat Gx platform to cover more compliance areas.
- Opportunity to cross-sell and upsell additional services to existing clients.
What Threats Does KSIOF Face?
- Intense competition from existing and emerging software providers in the compliance space.
- Potential for significant changes in regulatory frameworks that could impact demand or platform requirements.
- Economic downturns affecting R&D budgets and software adoption in life sciences.
- Risk of technological obsolescence if the platform does not continuously innovate.
What Are KSIOF's Competitive Advantages?
- Specialized COTS Platform: The Kneat Gx platform is purpose-built for validation lifecycle management in highly regulated industries, offering deep, specialized functionality that generic software solutions often lack.
- Regulatory Compliance Expertise: Possesses a deep understanding of complex regulatory requirements across biotechnology, pharma, and medical devices, which is embedded directly into the software's design and functionality.
- Comprehensive Service Suite: Offers end-to-end support from implementation and training to consulting and maintenance, creating a sticky customer relationship and ensuring successful platform adoption.
- Global Operational Footprint: Established presence in key markets like the US, Ireland, and Canada, enabling global client support and market reach for its specialized solutions.
What Does KSIOF Do?
Kneat.com, Inc. is a global provider of specialized software solutions, primarily focused on streamlining data and document management within highly regulated industries. Headquartered in Limerick, Ireland, the company has established a significant operational footprint across the United States, Ireland, and Canada, serving a diverse international client base. Its core offering is the Kneat Gx platform, a robust, configurable commercial off-the-shelf (COTS) application. This platform is meticulously engineered to manage the entire validation lifecycle and all associated testing processes, which are critical for compliance in sectors like biotechnology, pharmaceuticals, and medical device manufacturing. The Kneat Gx platform supports an extensive array of validation types, including process, computer system, cleaning, analytical instrument, method, utility and facility, equipment, and cold chain validation. Beyond validation, it also facilitates essential functions such as commissioning, qualification, and electronic logbook management, providing a holistic solution for complex regulatory environments. Kneat.com, Inc. augments its powerful software with a comprehensive suite of professional services. These services are crucial for successful client adoption and include implementation support, such specialized training and installation, system upgrades, expert consulting, and ongoing maintenance. The company further extends its expertise to strategic areas such as process mapping and project management, ensuring clients can fully leverage the Kneat Gx platform to enhance operational efficiency and maintain regulatory adherence. This integrated approach positions Kneat.com, Inc. as a key enabler of digital transformation in highly regulated industries.
What Products and Services Does KSIOF Offer?
- Provides software solutions for data and document management in highly regulated sectors.
- Offers the Kneat Gx platform, a configurable commercial off-the-shelf (COTS) application.
- Specializes in managing the entire validation lifecycle and associated testing processes.
- Serves biotechnology, pharmaceutical, and medical device manufacturing industries globally.
- Supports various validation types, including process, computer system, and equipment validation.
- Facilitates commissioning, qualification, and electronic logbook management.
- Complements its software with a suite of services like training, installation, upgrades, and consulting.
- Headquartered in Limerick, Ireland, with operations in the United States and Canada.
How Does KSIOF Make Money?
- Generates revenue primarily through software licensing or subscriptions for the Kneat Gx platform.
- Offers professional services, including implementation, training, and ongoing maintenance, as additional revenue streams.
- Provides expert consulting services for process mapping and project management.
- Focuses on enterprise clients in highly regulated industries, implying larger contract values.
- Aims for recurring revenue through long-term software agreements and service contracts.
What Industry Does KSIOF Operate In?
Kneat.com, Inc. operates within the Medical - Healthcare Information Services industry, a sector experiencing significant tailwinds from the broader trend of digital transformation. The company is specifically positioned in the niche of regulatory compliance software, targeting the biotechnology, pharmaceutical, and medical device manufacturing industries. These sectors are characterized by stringent regulatory requirements and complex validation processes, creating a substantial demand for specialized, efficient, and compliant software solutions. Kneat.com's Kneat Gx platform directly addresses this need by digitizing and automating validation lifecycles, moving away from traditional paper-based systems. The competitive landscape includes both smaller specialized software vendors and larger enterprise resource planning (ERP) providers that may offer modules with similar functionalities. Kneat.com differentiates itself through its dedicated COTS platform, purpose-built for validation, which often provides deeper functionality and faster implementation compared to generic solutions. The increasing pressure for operational efficiency and data integrity across the life sciences industry underpins the market opportunity for Kneat.com.
Who Are KSIOF's Key Customers?
- Biotechnology companies requiring rigorous validation for drug development and manufacturing processes.
- Pharmaceutical manufacturers needing to manage complex process, equipment, and computer system validations.
- Medical device manufacturers adhering to strict regulatory standards for product quality and safety.
- Organizations within highly regulated sectors globally seeking to digitize and automate compliance workflows.
- Companies looking for commercial off-the-shelf (COTS) solutions for efficient validation lifecycle management.
Company Profile
Kneat.com, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Limerick, IE. The company is led by CEO Edmund Ryan. KSIOF has traded publicly since 2014.
F-Score 4/9Financial Health
Kneat.com, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.46 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -13%Key Financial Metrics
Return on equity for Kneat.com, Inc. stands at -12.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.4%, the inverse of the P/E and a quick read on earnings relative to price.
KSIOF Valuation & Market Position
With a $442M market cap, Kneat.com, Inc. sits in the small-cap segment of the market. Relative to its peer group, KSIOF's quantitative score of 63/100 is roughly in line with the peer average of 62/100.
FY2026 estForward Outlook
Wall Street analysts project Kneat.com, Inc. revenue of about $79.2M for fiscal 2026, with EPS near $-0.09. The estimate reflects 5 contributing analysts.
KSIOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Kneat.com's recent insider buying suggests confidence from those who know the company best, signaling potential future growth.
- The general buzz in the social trading community around Kneat.com seems optimistic, indicating positive market perception.
- The company's focus on validation software for life sciences is gaining traction, positioning them well in a growing sector. Think of it like the early days of cloud computing – specialized solutions often lead to big gains.
- Bullish community members highlight Kneat.com's strong competitive advantage and potential for long-term contracts, similar to how Salesforce built its dominance.
Bear Case
- Some community members express concern about Kneat.com's ability to scale effectively to meet increasing demand, a challenge faced by many rapidly growing tech firms.
- There's a perception that Kneat.com's market valuation might already reflect much of its future potential, limiting near-term upside. This is similar to what happened with some hyped-up tech stocks in the dot-com bubble.
- Increased competition in the validation software space could erode Kneat.com's market share, posing a threat to its long-term growth.
- Bearish sentiment revolves around the company's reliance on specific industries, making it vulnerable to downturns in those sectors. This is a risk akin to companies heavily dependent on the automotive industry during economic recessions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
KSIOF Latest News
-
How The Kneat.com (TSX:KSI) Story Is Shifting Around A Tight Premium Valuation Range
Yahoo! Finance: KSIOF News · Jun 9, 2026
-
Kneat Enters into Definitive Agreement to be Acquired by Thoma Bravo in an All-Cash Transaction, Valuing Kneat at Approximately C$650 Million
globenewswire.com · Jun 8, 2026
-
Kneat Announces Results of Voting at Annual General Meeting
globenewswire.com · May 27, 2026
KSIOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KSIOF.
Price Targets
Wall Street price target analysis for KSIOF.
KSIOF MoonshotScore
What does this score mean?
The MoonshotScore rates KSIOF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
How The Kneat.com (TSX:KSI) Story Is Shifting Around A Tight Premium Valuation Range
Kneat Enters into Definitive Agreement to be Acquired by Thoma Bravo in an All-Cash Transaction, Valuing Kneat at Approximately C$650 Million
Kneat Announces Results of Voting at Annual General Meeting
Leadership: Edmund Ryan
CEO
Unknown. No specific background information, career history, education, or previous roles for Edmund Ryan were provided in the source data.
Track Record: Unknown. No specific achievements, strategic decisions, or company milestones under Edmund Ryan's leadership were provided in the source data.
KSIOF OTC Market Information
Kneat.com, Inc. trades on the OTC Other tier, which is the lowest of the three OTC Markets Group tiers (OTCQX, OTCQB, and OTC Pink). Companies on the OTC Other tier are typically not required to meet specific financial standards or file regular reports with the SEC, unlike companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited public information, making due diligence more challenging for investors. It signifies a less regulated trading environment compared to the higher OTC tiers, and significantly less stringent than national exchanges.
- OTC Tier: OTC Other
- Lower liquidity and wider bid-ask spreads compared to major exchanges.
- Limited public disclosure requirements, potentially hindering investor due diligence.
- Increased susceptibility to market manipulation due to less regulatory oversight.
- Difficulty in obtaining financing or attracting institutional investors due to OTC status.
- Potential for greater price volatility and less stable trading environment.
- Verify the company's current financial statements and audit reports directly from their investor relations.
- Research any recent news, press releases, and corporate actions beyond standard financial filings.
- Assess the management team's experience and track record through independent sources.
- Evaluate the company's business model, competitive advantages, and market position thoroughly.
- Understand the specific risks associated with the OTC Other tier and the company's industry.
- Examine the trading volume and bid-ask spread to gauge liquidity.
- Consult with a financial advisor experienced in OTC markets.
- The company has a clear, specialized business model in a high-demand sector (regulated software).
- It reports having 297 employees, indicating a substantive operational presence.
- Headquartered in Limerick, Ireland, suggesting a formal corporate structure.
- Its product, Kneat Gx, is described as a commercial off-the-shelf (COTS) application, implying a developed and marketable product.
- Operates globally with a presence in the United States, Ireland, and Canada.
Common Questions About KSIOF (Healthcare)
What does the AI Score mean for KSIOF?
KSIOF holds an AI Score of 63/100 (Grade: B+). This is an educational research signal, not a buy or sell recommendation. Kneat.com, Inc. provides the Kneat Gx platform, a specialized software solution for managing validation lifecycles and associated testing in highly regulated sectors like biotechnology …
What does Kneat.com, Inc. do?
Kneat.com, Inc. specializes in providing the Kneat Gx platform, a commercial off-the-shelf software solution designed for managing the entire validation lifecycle and associated testing in highly regulated industries. This includes sectors such as biotechnology, pharmaceuticals, and medical device manufacturing.
What are the key growth opportunities for KSIOF in healthcare?
Kneat.com, Inc. has several key growth opportunities within the healthcare and life sciences sectors. A primary driver is the ongoing digital transformation within biotechnology, pharmaceutical, and medical device manufacturing industries, which are increasingly seeking to automate and digitize complex validation processes. This trend creates a growing market for Kneat Gx.
What are the main risks for KSIOF?
Kneat.com, Inc. faces several notable risks. Operationally, the company currently reports a negative profit margin of -12.7% and a negative Return on Equity of -13.0%, indicating it is not yet profitable. The highly competitive landscape within regulatory software, with both specialized and broader enterprise solution providers, poses an ongoing threat.
What are the key factors to evaluate for KSIOF?
Kneat.com, Inc. (KSIOF) holds an AI score of 63/100 (moderate). Not financial advice.
How frequently does KSIOF data refresh on this page?
KSIOF's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KSIOF's recent stock price performance?
Kneat.com, Inc. (KSIOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized Kneat Gx platform addresses a critical niche in highly regulated industries. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KSIOF overvalued or undervalued right now?
Kneat.com, Inc. (KSIOF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KSIOF before investing?
Before investing in Kneat.com, Inc. (KSIOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived strictly from the provided source data. No external research or speculative content has been included. Specific details on CEO background, track record, competitor names, and OTC disclosure status were not available in the source and are marked as 'Unknown'.